The FDA approved a once-weekly subcutaneous starting dose of Leqembi Iqlik (lecanemab-irmb) for early Alzheimer's disease on July 13, 2026, letting patients begin treatment at home instead of starting with an IV infusion in a clinic, according to the FDA's approval notice. The new initiation regimen is self-administered or caregiver-administered from day one, raising practical questions about dosing, training, cost, and insurance coverage that this article answers. This matters for families managing early Alzheimer's or mild cognitive impairment due to Alzheimer's disease, the population lecanemab is approved to treat. The at-home option removes a barrier that kept some patients from starting therapy at all — regular infusion-center visits — but it also shifts new responsibilities onto patients and caregivers.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
- Read the official notice from Pharmatimes — Use this primary source to verify the official announcement.
Table of Contents
- What Is the New Starting Dose, and How Does It Work?
- What Testing and Precautions Are Required Before Starting?
- How Does Training for At-Home Injections Work?
- What Does This Cost, and Will Insurance Cover It?
- Frequently Asked Questions
What Is the New Starting Dose, and How Does It Work?
The approved initiation regimen is 500 mg given once weekly as two separate 250 mg injections, delivered subcutaneously (under the skin) through a prefilled autoinjector. Each injection takes about 15 seconds, according to the Eisai-Biogen launch announcement covered by PharmaTimes. This is a change from the original approval, which required patients to begin with an intravenous infusion given every two weeks at an infusion center. Subcutaneous lecanemab-irmb can now be given by the patient or a caregiver starting with the very first dose, according to Drug Topics.
Patients no longer need an initial in-clinic IV visit to begin therapy — the autoinjector dose can replace that step entirely. After 18 months on either the IV regimen (10 mg/kg every two weeks) or the subcutaneous starting dose, patients move to maintenance dosing: 360 mg subcutaneously once a week, or they can continue IV infusions every four weeks instead. Switching between the IV and subcutaneous routes is allowed, according to the Eisai/Biogen press release. This gives families flexibility if a patient's situation changes — for example, moving from a clinic-based routine to home administration, or the reverse if side effects or logistics make home dosing difficult. The FDA based this approval on pharmacokinetic data showing that subcutaneous dosing produces drug exposure equivalent to the IV route, combined with open-label extension sub-studies from the Clarity AD trial — not a new standalone phase 3 trial, according to coverage from AJMC.
What Testing and Precautions Are Required Before Starting?
Before any patient starts lecanemab, FDA's prescribing information requires ApoE ε4 genotype testing. This gene variant affects the risk of a side effect called ARIA, or amyloid-related imaging abnormalities — swelling or small bleeds in the brain that show up on MRI scans. The prescribing information also carries warnings about increased risk of intracerebral hemorrhage in patients taking blood thinners (anticoagulants), hypersensitivity reactions, and injection-site reactions, according to the FDA's approval notice.
These requirements don't change because the drug can now be given at home. A patient still needs genetic testing and the monitoring their neurologist determines necessary before the first injection, regardless of whether that injection happens in a clinic or a living room. One advantage cited for the subcutaneous route: Eisai reported systemic injection-related reactions in under 1% of patients in its sub-studies, compared with roughly 26% of patients experiencing infusion-related reactions on the IV regimen, according to the Eisai/Biogen press release. Injection-site reactions — redness or swelling where the shot was given — are a separate, distinct risk from the systemic reactions associated with IV infusions.
How Does Training for At-Home Injections Work?
Eisai and Biogen provide patient and caregiver injection-training materials, along with treatment-tracking tools, specialty-pharmacy support, and financial assistance for eligible uninsured patients, as part of the at-home launch, according to Epocrates. This support structure is designed to walk a patient or caregiver through the autoinjector technique before they administer a dose unsupervised. For a caregiver taking on this task, the practical steps typically include: Because the two 250 mg injections are given separately, caregivers administering the dose need to confirm both injections are completed each week, not just one.
- Reviewing training materials provided through the specialty pharmacy before the first at-home dose
- Confirming ApoE ε4 testing and any required baseline monitoring are complete
- Learning to recognize injection-site reactions versus signs that warrant calling the prescribing neurologist
- Keeping track of the weekly dosing schedule using the tracking tools Eisai and Biogen supply
- Knowing who to contact — the specialty pharmacy or the prescriber's office — if a dose is missed or a reaction occurs
What Does This Cost, and Will Insurance Cover It?
The subcutaneous maintenance autoinjector launched in the US on October 6, 2025, at a wholesale acquisition cost of $375 per injection, or about $19,500 a year. The initiation-dose version of the autoinjector followed with its commercial US launch in late August 2026, according to PharmaTimes. Insurance coverage for the at-home starting dose is not guaranteed to match the FDA's approval right away.
Mass General Brigham Health Plan's policy, effective March 1, 2026, covers subcutaneous Leqembi only as a maintenance option after a patient has completed at least 18 months of IV therapy — it requires specialist prescribing and does not allow combining IV and subcutaneous use, according to the plan's published policy. That policy predates the July 2026 initiation-dose approval, so it illustrates a broader pattern: payer rules can lag behind what the FDA has approved, and a plan's prior authorization criteria may not yet reflect the at-home starting option. Patients and caregivers considering the at-home starting dose should ask their insurer directly whether the subcutaneous initiation regimen is covered as a first-line option, or whether the plan still requires IV therapy first. The answer may depend on which plan a patient has and when that plan last updated its policy relative to the July 2026 approval.
Frequently Asked Questions
Can a patient start Leqembi at home without ever going to an infusion center?
Yes. The subcutaneous starting dose approved July 13, 2026 allows the first dose to be given at home by the patient or a caregiver, replacing the IV infusion that previously had to come first, according to the FDA's approval notice.
Is the at-home starting dose the same drug as the original IV version?
It's the same drug, lecanemab-irmb, given through a different route. The FDA approved subcutaneous dosing based on pharmacokinetic data showing equivalent drug exposure to IV dosing, plus data from the Clarity AD trial's open-label extension, rather than a new phase 3 trial.
Does starting at home skip any required testing?
No. ApoE ε4 genotype testing is still required before starting treatment regardless of whether the first dose is given by IV or by at-home injection.
You Might Also Like
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: Access, Cost, and Follow-Up Questions for People With Mild Cognitive Impairment
- How 2026 Tau Imaging News May Affect Alzheimer’s Workups: Access, Cost, and Follow-Up Questions for People With Mild Cognitive Impairment
- Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: A Preparation Checklist for People With Mild Cognitive Impairment
